Bimekizumab gets PIM designation from MHRA for hidradenitis

Belgium’s largest pharma company UCB (Euronext: UCB) today revealed that its developmental treatment for adults with hidradenitis suppurativa (HS) has been granted Promising Innovative Medicine (PIM) designation in the UK by the Medicines and Healthcare Products Regulatory Agency (MHRA).

Claire Brading, managing director, UCB UK said: “Hidradenitis suppurativa is a debilitating condition and we are delighted that the MHRA has recognized the potential of bimekizumab for patients living with the chronic pain of this disease. This is testament to our commitment to supporting patients with skin conditions in the UK and harnessing innovative science to do so.”

The company pointed out that the granting of a PIM designation is an early indication that an investigational treatment may be an eligible candidate for Early Access to Medicines (EAMS), which can provide patients with life threatening or seriously  debilitating conditions pre-approval access to medicines where there is a clear unmet medical need. PIM is granted to products that meet all three of the following criteria.